Market Overview:
The global marburgvirus infection market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of marburgvirus infections, rising awareness about marburgvirus infections, and increasing funding for research and development activities for the treatment of marburgvirus infections. However, the high cost of treatment may restrain the growth of this market during the forecast period. The global Marburg virus infection market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into eritoran tetrasodiums AR-12s ARD-5s AVI-7288s and others.
Product Definition:
Marburgvirus Infection is a type of viral hemorrhagic fever. It is caused by the Marburg virus, and is a serious and often deadly disease. Symptoms include fever, headache, muscle pain, vomiting, and diarrhea. In severe cases there may be bleeding from the nose or mouth, seizures, or organ failure. The virus is spread through contact with infected blood or body fluids. It can also be spread through close contact with an infected animal such as a monkey or bat.
Eritoran Tetrasodium:
Eritoran tetrasodium is a chemical compound of sodium and four ethyl groups. It was first synthesized in 1960 by a group of scientists at the University of Maine, U.S., and has been under continuous research since then.
AR-12:
AR-12 is a nucleoside analog that acts as an antiviral agent. It has been found to inhibit the growth of the virus in cell culture when used at nanomolar concentrations (10-8 M). The drug has also shown activity against Marburgvirus, a hemorrhagic fever virus. AR-12 was granted Fast Track Designation by FDA for use as a treatment for Lassa fever, one of the most dangerous viral hemorrhagic fever diseases.
Application Insights:
The hospital application segment led the market in 2017 and is projected to expand at a revenue-based CAGR of XX% over the forecast period. The growing number of marburgvirus disease cases across hospitals globally has resulted in an increased demand for diagnostic tests, which, in turn, is anticipated to boost industry growth over the coming years.
Clinical trials are being conducted with regard to marburgvirus infection as it pertains to cancer treatment and development of vaccines against this virus. Thus, numerous research studies are ongoing regarding its usage as a therapeutic agent against various diseases such as cancer & oncolysis; HIV; hepatitis B & C; etc., which provide potential avenues for growth during the forecast period.
The others application segment includes animal testing facilities.
Regional Analysis:
North America dominated the global marburgvirus infection market in 2017. The presence of a strong healthcare infrastructure and high R&D investment by the government are some factors responsible for its large share. Furthermore, increasing cases of Marburg virus disease are fueling the demand for diagnostic tests and therapeutics in this region.
On the other hand, Asia Pacific is expected to be fastest growing regional market over the forecast period owing to continuous rise in awareness about various treatment options along with rapid economic development taking place in this region especially India China Japan Indonesia Thailand Philippines Malaysia Singapore South Korea Vietnam Myanmar Australia New Zealand and so on’s which will fuel growth during forecast period.
Growth Factors:
- Increasing incidence of Marburg virus infection due to the exposure to infected animals or their tissues and body fluids.
- Growing awareness about the symptoms and risk factors associated with Marburg virus infection is likely to boost the demand for diagnostic tests and treatment options over the forecast period.
- The increasing number of research activities on development of novel therapeutics for treatment of Marburg virus infection is expected to propel market growth during the forecast period.
- Rising number of travel-related cases owing to globalization is anticipated to fuel market growth in near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Marburgvirus Infection Market Research Report
By Type
Eritoran Tetrasodium, AR-12, ARD-5, AVI-7288, Others
By Application
Hospital, Clinic, Others
By Companies
Arno Therapeutics Inc, BioCryst Pharmaceuticals Inc, Eisai Co Ltd, Emergent BioSolutions Inc, Fab'entech SA, Integrated BioTherapeutics Inc, Johnson & Johnson, NanoViricides Inc, Profectus BioSciences Inc, Rodos BioTarget GmbH, Sarepta Therapeutics Inc, Theravectys SA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Marburgvirus Infection Market Report Segments:
The global Marburgvirus Infection market is segmented on the basis of:
Types
Eritoran Tetrasodium, AR-12, ARD-5, AVI-7288, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Arno Therapeutics Inc
- BioCryst Pharmaceuticals Inc
- Eisai Co Ltd
- Emergent BioSolutions Inc
- Fab'entech SA
- Integrated BioTherapeutics Inc
- Johnson & Johnson
- NanoViricides Inc
- Profectus BioSciences Inc
- Rodos BioTarget GmbH
- Sarepta Therapeutics Inc
- Theravectys SA
Highlights of The Marburgvirus Infection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Eritoran Tetrasodium
- AR-12
- ARD-5
- AVI-7288
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Marburgvirus Infection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Marburgvirus is a virus that can cause severe illness in humans. It is a member of the family of viruses that includes Ebola and SARS (severe acute respiratory syndrome). Marburgvirus infection most often occurs in Africa, Asia, and Europe. The virus causes severe fever, muscle pain, vomiting, diarrhea, and rash. In some cases the virus can lead to pneumonia or even death. There is no specific treatment for marburgvirus infection; however supportive care may help to improve symptoms. Prevention involves avoiding contact with people who are infected with the virus and using effective protection against mosquito bites
Some of the key players operating in the marburgvirus infection market are Arno Therapeutics Inc, BioCryst Pharmaceuticals Inc, Eisai Co Ltd, Emergent BioSolutions Inc, Fab'entech SA, Integrated BioTherapeutics Inc, Johnson & Johnson, NanoViricides Inc, Profectus BioSciences Inc, Rodos BioTarget GmbH, Sarepta Therapeutics Inc, Theravectys SA.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Marburgvirus Infection Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Marburgvirus Infection Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Marburgvirus Infection Market - Supply Chain
4.5. Global Marburgvirus Infection Market Forecast
4.5.1. Marburgvirus Infection Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Marburgvirus Infection Market Size (000 Units) and Y-o-Y Growth
4.5.3. Marburgvirus Infection Market Absolute $ Opportunity
5. Global Marburgvirus Infection Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Marburgvirus Infection Market Size and Volume Forecast by Type
5.3.1. Eritoran Tetrasodium
5.3.2. AR-12
5.3.3. ARD-5
5.3.4. AVI-7288
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Marburgvirus Infection Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Marburgvirus Infection Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Marburgvirus Infection Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Marburgvirus Infection Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Marburgvirus Infection Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Marburgvirus Infection Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Marburgvirus Infection Demand Share Forecast, 2019-2026
9. North America Marburgvirus Infection Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Marburgvirus Infection Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Marburgvirus Infection Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Marburgvirus Infection Market Size and Volume Forecast by Type
9.7.1. Eritoran Tetrasodium
9.7.2. AR-12
9.7.3. ARD-5
9.7.4. AVI-7288
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Marburgvirus Infection Demand Share Forecast, 2019-2026
10. Latin America Marburgvirus Infection Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Marburgvirus Infection Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Marburgvirus Infection Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Marburgvirus Infection Market Size and Volume Forecast by Type
10.7.1. Eritoran Tetrasodium
10.7.2. AR-12
10.7.3. ARD-5
10.7.4. AVI-7288
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Marburgvirus Infection Demand Share Forecast, 2019-2026
11. Europe Marburgvirus Infection Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Marburgvirus Infection Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Marburgvirus Infection Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Marburgvirus Infection Market Size and Volume Forecast by Type
11.7.1. Eritoran Tetrasodium
11.7.2. AR-12
11.7.3. ARD-5
11.7.4. AVI-7288
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Marburgvirus Infection Demand Share, 2019-2026
12. Asia Pacific Marburgvirus Infection Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Marburgvirus Infection Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Marburgvirus Infection Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Marburgvirus Infection Market Size and Volume Forecast by Type
12.7.1. Eritoran Tetrasodium
12.7.2. AR-12
12.7.3. ARD-5
12.7.4. AVI-7288
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Marburgvirus Infection Demand Share, 2019-2026
13. Middle East & Africa Marburgvirus Infection Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Marburgvirus Infection Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Marburgvirus Infection Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Marburgvirus Infection Market Size and Volume Forecast by Type
13.7.1. Eritoran Tetrasodium
13.7.2. AR-12
13.7.3. ARD-5
13.7.4. AVI-7288
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Marburgvirus Infection Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Marburgvirus Infection Market: Market Share Analysis
14.2. Marburgvirus Infection Distributors and Customers
14.3. Marburgvirus Infection Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Arno Therapeutics Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. BioCryst Pharmaceuticals Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eisai Co Ltd
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Emergent BioSolutions Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Fab'entech SA
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Integrated BioTherapeutics Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Johnson & Johnson
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. NanoViricides Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Profectus BioSciences Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Rodos BioTarget GmbH
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Sarepta Therapeutics Inc
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Theravectys SA
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
